Western Institutional Review Board

Western Institutional Review Board
Name	Western Institutional Review Board
Type	Independent ethics review board
Founded	1968
Founders	Fred A. Thompson; Robert L. Coleman
Headquarters	Puyallup, Washington
Key people	Daniel Y. Fink; Lucinda M. Miller
Products	Ethics review, protocol review, safety monitoring

Western Institutional Review Board

Western Institutional Review Board provided independent ethics review services for clinical trial sponsors, pharmaceutical industry firms, and academic investigators engaged in human subjects research. It operated within the landscape shaped by the National Research Act, the Belmont Report, and oversight from agencies such as the Food and Drug Administration and the Office for Human Research Protections. The board advised on protocols influenced by legislation including the Common Rule and engaged with institutions such as Johns Hopkins University, Mayo Clinic, and multinational companies like Pfizer and Novartis.

History

Founded in 1968 by figures including Fred A. Thompson and Robert L. Coleman, the organization emerged amid debates following the Tuskegee syphilis study revelations and implementation of the National Research Act. During the 1970s and 1980s it interacted with scholars from Harvard University and University of Pennsylvania who shaped institutional review practices, and it evolved alongside regulatory actions by the Food and Drug Administration and the Department of Health and Human Services. In the 1990s and 2000s it expanded services to multinational trials run by GlaxoSmithKline, AstraZeneca, and Johnson & Johnson, while responding to guidances from the World Medical Association and its Declaration of Helsinki. The organization’s trajectory intersected with corporate consolidation trends exemplified by mergers involving Quorum Review IRB and other private review entities.

Structure and Governance

The board maintained a roster of reviewers drawn from clinical and ethical leaders affiliated with institutions such as Stanford University, University of California, San Francisco, and Massachusetts General Hospital. Governance incorporated policies informed by standards from Association for the Accreditation of Human Research Protection Programs, with oversight mechanisms comparable to committees at Yale University and Columbia University. Executive leadership coordinated legal counsel experienced with statutes like the Health Insurance Portability and Accountability Act and regulatory strategy used by in-house teams at Merck and Eli Lilly and Company. Committees included specialists in areas linked to entities such as Centers for Disease Control and Prevention, World Health Organization, and academic centers including University of Oxford and Karolinska Institutet.

Functions and Services

Services encompassed expedited and full-board review of protocols for sponsors including Bristol-Myers Squibb and contract research organizations akin to IQVIA, as well as safety monitoring comparable to data safety monitoring boards for trials at Cleveland Clinic and UCSF Medical Center. The board provided informed consent review influenced by rulings from the Supreme Court of the United States and guidance from agencies like European Medicines Agency and Health Canada. It offered ancillary services—privacy compliance informed by HIPAA interpretations used by Kaiser Permanente, liability assessment paralleling counsel at Covington & Burling, and multicenter coordination reminiscent of practices at National Institutes of Health and multicenter networks such as Duke Clinical Research Institute.

Accreditation and Compliance

Accreditation efforts aligned with standards from Association for the Accreditation of Human Research Protection Programs and reflected expectations articulated by the Office for Human Research Protections. Compliance frameworks referenced regulatory regimes enforced by the Food and Drug Administration and international norms advanced by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The organization engaged with audits like those used by Centers for Medicare & Medicaid Services contractors and internal controls similar to practices at Galenica AG-style providers. Its compliance posture was periodically evaluated in contexts paralleling oversight of university IRBs at University of Michigan and University of Washington.

Controversies and Criticism

The board faced criticism drawn from cases compared to debates around institutional review at Johns Hopkins University and Duke University Medicine Center about commercialization of review services and potential conflicts of interest involving sponsors such as GlaxoSmithKline and Pfizer. Commentators referenced ethical critiques prominent in discussions involving scholars from Georgetown University and Princeton University concerning independence, turnaround times, and depth of review. High-profile media coverage resembling investigations into research oversight at The New York Times and The Washington Post prompted scrutiny analogous to controversies that implicated private review models in debates featured at forums hosted by The Hastings Center and The Kennedy Institute of Ethics.

Impact and Contributions to Research Ethics

The board influenced the professionalization of review processes adopted by academic centers including Columbia University, Northwestern University, and Brown University, and it contributed to operational models used by contract research organizations like PAREXEL and ICON plc. Its procedures informed consent templates and risk assessments referenced in guidance by World Health Organization working groups and ethics curricula at University of Oxford and King's College London. Debates surrounding its practices spurred scholarship from ethicists at Harvard Medical School, University of Chicago, and University of Toronto that shaped subsequent revisions of the Common Rule and international regulatory harmonization efforts championed by the International Council for Harmonisation.

Category:Institutional review boards